Background and Aims:Liver enzyme abnormalities in coronavirus 2019(COVID-19)are being addressed in the literature.The predictive risk of elevated liver enzymes has not been established for COVID-19 mortality.In this s...Background and Aims:Liver enzyme abnormalities in coronavirus 2019(COVID-19)are being addressed in the literature.The predictive risk of elevated liver enzymes has not been established for COVID-19 mortality.In this study,we hypothesized that elevated liver enzymes at ad-mission can predict the outcome of COVID-19 disease with other known indicators,such as comorbidities.Methods:This retrospective study included all the consecutive hos-pitalized patients with confirmed COVID-19 disease from March 4th to May 31st,2020.The study was conducted in Rajiv Gandhi Government General Hospital,Chennai,Ta-mil Nadu,India.We assessed demography,clinical vari-ables,COVID-19 severity,laboratory parameters,and out-come.Results:We included 1,512 patients,and median age was 47 years(interquartile range:34-60)with 36.9%being female.Liver enzyme level(aspartate aminotrans-ferase and/or alanine aminotransferase)was elevated in 450/1,512(29.76%)patients.Comorbidity was present in 713/1,512(47.16%)patients.Patients with liver enzymes’elevation and presence of comorbidity were older,more frequently hospitalized in ICU and had more severe symp-toms of COVID-19 at the time of admission.Presence of liver enzymes’elevation with comorbidity was a high risk factor for death(OR:5.314,95%CI:2.278-12.393),as compared to patients with presence of comorbidity(OR:4.096,95%CI:1.833-9.157).Conclusions:Comorbid-ity combined with liver enzymes’elevation at presentation independently increased the risk of death in COVID-19 by at least 5-fold.展开更多
文摘Background and Aims:Liver enzyme abnormalities in coronavirus 2019(COVID-19)are being addressed in the literature.The predictive risk of elevated liver enzymes has not been established for COVID-19 mortality.In this study,we hypothesized that elevated liver enzymes at ad-mission can predict the outcome of COVID-19 disease with other known indicators,such as comorbidities.Methods:This retrospective study included all the consecutive hos-pitalized patients with confirmed COVID-19 disease from March 4th to May 31st,2020.The study was conducted in Rajiv Gandhi Government General Hospital,Chennai,Ta-mil Nadu,India.We assessed demography,clinical vari-ables,COVID-19 severity,laboratory parameters,and out-come.Results:We included 1,512 patients,and median age was 47 years(interquartile range:34-60)with 36.9%being female.Liver enzyme level(aspartate aminotrans-ferase and/or alanine aminotransferase)was elevated in 450/1,512(29.76%)patients.Comorbidity was present in 713/1,512(47.16%)patients.Patients with liver enzymes’elevation and presence of comorbidity were older,more frequently hospitalized in ICU and had more severe symp-toms of COVID-19 at the time of admission.Presence of liver enzymes’elevation with comorbidity was a high risk factor for death(OR:5.314,95%CI:2.278-12.393),as compared to patients with presence of comorbidity(OR:4.096,95%CI:1.833-9.157).Conclusions:Comorbid-ity combined with liver enzymes’elevation at presentation independently increased the risk of death in COVID-19 by at least 5-fold.
